Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders.

##STR00001##

Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders.

##STR00001##

Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

The invention relates to a compound of Formula (I), wherein n is 0 or 1, R.sub.1 is H or CH.sub.3 and R.sub.2 is a linear (C.sub.3-C.sub.6)alkyl and an insecticide composition comprising at least one insecticide active ingredient and at least one a compound of Formula (I).

The invention relates to a compound of Formula (I), wherein n is 0 or 1, R.sub.1 is H or CH.sub.3 and R.sub.2 is a linear (C.sub.3-C.sub.6)alkyl and an insecticide composition comprising at least one insecticide active ingredient and at least one a compound of Formula (I).

Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders. ##STR00001##

Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders. ##STR00001##

Compounds of formula (IIc); wherein X.sup.3 and X.sup.4 independently from each other are N or CR.sup.8 wherein R.sup.8 may be same or different; Y.sup.1, Y.sup.2, Y.sup.3 and Y.sup.4 independently from each other are N or CR.sup.9 wherein R.sup.9 may be same or different and wherein up to 3 of the group Y.sup.1, Y.sup.2, Y.sup.3 and Y.sup.4 may be N; their solvates, hydrates, and pharmaceutically acceptable salts, their use for modulating the Wnt signalling pathway activity and their use as a medicament, preferably for the treatment of cancer.

##STR00001##

Compounds of formula (IIc); wherein X.sup.3 and X.sup.4 independently from each other are N or CR.sup.8 wherein R.sup.8 may be same or different; Y.sup.1, Y.sup.2, Y.sup.3 and Y.sup.4 independently from each other are N or CR.sup.9 wherein R.sup.9 may be same or different and wherein up to 3 of the group Y.sup.1, Y.sup.2, Y.sup.3 and Y.sup.4 may be N; their solvates, hydrates, and pharmaceutically acceptable salts, their use for modulating the Wnt signalling pathway activity and their use as a medicament, preferably for the treatment of cancer.

##STR00001##